Impact of chemotherapy on early ageing in testicular cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of cisplatin-combination chemotherapy on the development of senescent cells and an early ageing phenotype in patients with metastatic testicular cancer. It aims to understand how chemotherapy-induced DNA damage affects both tumor and healthy cells, potentially leading to long-term health consequences. The study includes both cross-sectional and longitudinal components, involving skin and subcutaneous fat biopsies to assess cellular changes. By examining these effects, the researchers hope to uncover mechanisms behind late effects of treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

In order to be eligible to participate in the cross-sectional part of this study, a subject must meet all of the following criteria:

* Diagnosed with metastatic testicular cancer in 1999-2012 (stage II or higher)
* Received first-line cisplatin-based chemotherapy
* Was younger than 50 years of age at start of chemotherapy

In order to be eligible to participate in the longitudinal part of this study, a subject must meet all of the following criteria:

Chemotherapy-group:

* Diagnosis of metastatic testicular cancer (stage II or higher)
* Is about to start with first-line cisplatin-based chemotherapy
* Younger than 50 years of age at diagnosis of metastatic testicular cancer

Stage I control-group:

* Diagnosis of testicular cancer stage I disease
* Younger than 50 years of age at diagnosis of testicular cancer

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

\- Not able to provide informed consent (in example in case of mental or psychiatric disability)

Where it's running

• University Medical Center Groningen
  Groningen, Netherlands Recruiting

Study contacts

• Principal investigator: J. A. Gietema, Prof. — University Medical Center Groningen
• Study coordinator: J. A. Gietema, prof.
• Email: j.a.gietema@umcg.nl
• Phone: +31 50 361 2821

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Primary retroperitoneal lymph node surgery versus chemotherapy for good‑prognosis metastatic testicular cancer

  This study will test whether primary RPLND (surgery) instead of standard chemotherapy leads to fewer side effects and better quality of life for men 18 and older with good‑prognosis metastatic testicular cancer.

  Recruiting Sahlgrenska University Hospital · Gothenburg, Göteborg · NCT07498959

• Sodium thiosulfate to protect hearing during cisplatin therapy in adults with solid tumors

  This study tests Pedmark sodium thiosulfate to see if it reduces hearing loss in adults receiving standard cisplatin chemotherapy.

  Recruiting Phase 1/2 University of Arizona · Tucson, Arizona · NCT07407582

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• How retroperitoneal lymph node dissection affects urination and sexual function

  This project will see if retroperitoneal lymph node dissection (RPLND) for testicular cancer changes urination, ejaculation, erections, and quality of life in adult men.

  Recruiting Jagiellonian University · Krakow, Malopolska · NCT06954233

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.